Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPERT trial of exemestane in hormone receptor-positive epithelial ovarian cancer
2018-000693-30Phase 3Terminated
- Sponsor
- Ospedali Galliera
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in epithelial ovarian cancer (EOC) comparing Exemestane plus standard first-line treatment with Placebo plus standard first-line treatment (2 arms). Primary endpoint: Progression-free survival. Started Oct 2019; status: terminated.
02
Drugs
exemestane
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2018-000693-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000693-30.